People who used lipophilic (fat-soluble) statins like atorvastatin and simvastatin had the greatest outcomes and ...

HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and hepatic decompensation, according to a study published ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with researchers from the Agency for Science, Technology and Research and Chinese ...

Undisclosed Conflicts of Interest in Japanese Cancer Clinical Trials: A Cross-Sectional Study of Author-Pharmaceutical Industry Financial Relationships Global incidence of hepatocellular carcinoma ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with collaborators from the Agency for Science, ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

BLA accepted Pembrolizumab (Merck) Anti-programmed death receptor-1 (PD-1) therapy For the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma as ...